Your session is about to expire
← Back to Search
Unknown
QLS-101 for Ocular Hypertension
Phase 2
Waitlist Available
Research Sponsored by Qlaris Bio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 100 days
Awards & highlights
Study Summary
This study is evaluating whether a new drug may be safer than an existing drug for individuals with glaucoma or ocular hypertension.
Eligible Conditions
- Ocular Hypertension
- Glaucoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 100 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~100 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Ocular safety
Secondary outcome measures
Ocular hypotensive efficacy
Side effects data
From 2015 Phase 4 trial • 157 Patients • NCT020033916%
Ocular hyperaemia
5%
Eye pruritus
2%
Nasopharyngitis
2%
Dry eye
1%
Acute tonsillitis
1%
Pharyngitis
1%
Conjunctivitis allergic
1%
Eyelids pruritus
1%
Blepharal pigmentation
1%
Eye irritation
1%
Cataract
1%
Arthritis
1%
Hypersensitivity
1%
Eye pain
1%
Ocular surface disease
100%
80%
60%
40%
20%
0%
Study treatment Arm
DuoTrav
Beta-blocker
Trial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: QLS-101 2%Experimental Treatment1 Intervention
Group II: QLS-101 1%Experimental Treatment1 Intervention
Group III: QLS-101 0.5%Experimental Treatment1 Intervention
Group IV: Timolol Maleate 0.5% preservative free ophthalmic solutionActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
QLS-101
2021
Completed Phase 2
~120
Find a Location
Who is running the clinical trial?
Qlaris Bio, Inc.Lead Sponsor
6 Previous Clinical Trials
263 Total Patients Enrolled
4 Trials studying Ocular Hypertension
113 Patients Enrolled for Ocular Hypertension
Share this study with friends
Copy Link
Messenger